2024 World Conference on Lung Cancer (WCLC) - Posters-P2.07C.01 LCMC3: Clinical Utility of Suvmax on Preoperative 18F-FDG PET-CT in Resectable NSCLC Treated with Neoadjuvant Atezolizumab

P2.07C.01 LCMC3: Clinical Utility of Suvmax on Preoperative 18F-FDG PET-CT in Resectable NSCLC Treated with Neoadjuvant Atezolizumab

Back to course

Pdf Summary

The 2024 World Conference on Lung Cancer featured a study evaluating the effectiveness of neoadjuvant atezolizumab treatment in patients with resectable non-small cell lung cancer (NSCLC). This treatment involves assessing the change in SUVmax, which measures tumor metabolic activity through FDG uptake.<br /><br />The study enrolled 181 patients, of which 159 underwent surgical resection. The analysis focused on 119 patients with paired PET-CT scans conducted before and after treatment. Results showed that patients with decreased SUVmax post-treatment had significantly better clinical outcomes, including higher rates of major pathological response (MPR) and 3-year overall survival (OS), compared to those with increased SUVmax. Specifically, the 3-year OS was 88% for decreased SUVmax patients versus 72% for increased SUVmax patients. Additionally, a higher percentage of PD-L1high tumors, characterized by TPS 50%, was found in patients with decreased SUVmax. <br /><br />The findings suggest that assessing changes in SUVmax could serve as a valuable predictive tool for clinicians regarding patient response to neoadjuvant atezolizumab before surgical intervention in NSCLC cases. However, further research is needed to validate these findings and improve patient stratification for treatment. The study was supported by Genentech and included contributions from several prominent institutions. <br /><br />The research underscores the potential of SUVmax as a non-invasive diagnostic measure but notes the importance of broader evaluations for integrating this metric into routine clinical practice for treating resectable NSCLC.

Asset Subtitle

Robert Merritt

Meta Tag

Speaker Robert Merritt

Topic Early-Stage NSCLC

Keywords

World Conference on Lung Cancer

neoadjuvant atezolizumab

non-small cell lung cancer

SUVmax

FDG uptake

major pathological response

3-year overall survival

PD-L1high tumors

patient stratification

Genentech